Compare Regeneron Pharmaceuticals Inc (REGN) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs WD 40 Company — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while WD 40 Company trades at $199.54 (market cap $2.71B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 30.8× WD 40 Company's market cap, and WD 40 Company pays the higher dividend (2.02%). Which is the better fit depends on your goals.
| REGN | WDFC | |
|---|---|---|
Market Cap | $83.43B | $2.71B |
Sector | Health | Technology |
52-Week High | $852.03 | $264.91 |
52-Week Low | $555.51 | $187.52 |
Enterprise Value | $78.14B | $2.76B |
Dividend Yield | 0.46% | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
WDFC trades at $201.73, down 2.81% today, with a bearish technical signal but strong fundamentals. Recent earnings show mixed results with a Q4 2025 miss but Q1 and Q2 2026 beats. The company maintains robust profitability with a 55.82% gross margin and 13.22% net margin. News highlights strong Q3 2026 performance and strategic growth initiatives including global expansion and digital transformation.
Outlook is cautiously optimistic with solid brand loyalty and growth potential, but risks include input cost pressures and valuation concerns. Analyst consensus is mixed with a 'Hold' majority. The stock's current price near support at $199 suggests potential stability if fundamentals hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
